Together, these results demonstrate that elevated metabolic risk, as indicated by high MRPs scores and WARS2 expression, is associated with reduced immune infiltration and an immunosuppressive tumor milieu—potentially underlying the poor prognosis observed in the MRP I subgroup. The gene discussed is MRPS7; the disease is neoplasm.